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The efficacy of the protein synthesis inhibitor ethyldes­
hydroxy-sparsomycin (EDSM) as a biochemical response 
modifier of several antitumor agents against L1210 leu­
kemia and B16 melanoma is described. Seven drugs with 
different intracellular targets were selected for this com­
bination study. Tumor implantation and drug treatment 
were both i.p», and the time interval between the admin­
istration of EDSM and the cytostatic agent was varied. 
Our results show that In the B16 tumor model EDSM is 
not able to potentiate any of these drugs, whereas an­
tagonism is seen in combination with doxo-rubicln (DX). 
In the L1210 tumor model, however, no loss of activity is 
seen for this specific combination. The effect of the 
combination of cytosar (Ara-C), 5-fluorouracll (5-FU) or 
vincristine (VCR) with EDSM in the L1210 model Is 
strongly time interval dependent. Loss of 5-FU antitumor 
activity is seen when EDSM is given 3 or 24 h after 5-FU; 
however, no effect Is observed when EDSM Is given 6 h 
after 5-FU. Enhancement of the 5-FU activity is not no­
ticed. The VCR activity Is potentiated when EDSM is given 
at least 6 h after VCR administration, which Increases the 
antitumor response from 32 to >60 days and the per­
centage survivors from 33 to 83% (p = 0,04), In combina­
tion with Ara-C, potentiation of antitumor activity is seen 
only when EDSM Is given 24 h after Ara-C, which in­
creases the antitumor response from 32 to >55 days 
and the percentage survivors from 11 to 50% (p =
0.008). No modulatory effects are found when EDSM is 
combined with carmustine or DX. Our results suggest 
that EDSM changes the antitumor efficacy of selected 
antitumor agents (Ara-C and VCR) In a schedule-depen­
dent way and that potentiation Is largely restricted to cell- 
cycle phase-specific cytostatic agents.
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introduction
Incomplete revsponse of malignancies to antineo­
plastic agents remains a major clinical problem. 
Sometimes their efficacy can be improved by 
combining cytostatic agents with different modes 
of action, but non-chemotherapeutic agents are also 
capable of improving the efficacy of cyto­
statics, e.g. by reversing the resistance to chemo­
therapy.
Sparsomyein and its analogs are inhibitors of ribo- 
somal protein synthesis,1“'1 and previous reports 
from our laboratory clearly demonstrated that these 
compounds potentiate the antitumor activity of cis- 
platin in vivo*“7 Furthermore, it was shown that the 
effect of combined treatment of cisplatin and ethyl­
deshydroxy-sparsomycin (EDSM) was independent 
of administration order.7 This potentiation was not a 
result of pharmacological factors, but was strongly 
dependent on the cellular properties of the target 
tumor-cell populations.w Comparison of Che cellular 
basis of drug sensitivity of solid tumors with that of 
leukemia cells suggests that a large part of the re­
sistance of solid tumors to treatment is due to low 
drug sensitivity of the tumor cell itself.9 Another 
parameter might be that the sensitivity of tumor cells 
as well as the cytotoxicity of drug combinations may 
depend on the schedule of administration as well as 
the doses used .10'11
To investigate * I4 h n;r the synergistic effect of
EDSM on cisplatin's efficacy is a general phenom­
enon of EDSM that is applicable to other anticancer 
drugs, we studied the effect of EDSM on the anti­
tumor activity of agents with different intracellular 
targets. Moreover, we searched for the optimal dose 
ratio and schedule dependency for maximal anti- 
tumor enhancement by EDSM.
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Material and methods
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Drugs
Tumor cells
Murine LI 210 leukemia cells and B l6 melanoma 
were kindly supplied by Dr G Atassi (Institute 
Jules Bordet, Laboratory for Experimental 
Chemotherapy, Brussels, Belgium). L1210 leukemia 
cells were maintained in logarithmic growth as 
suspension culture and B16 melanoma cells were 
grown routinely as a monolayer culture at 37°C in 
a humidified atmosphere of 5% C0 2 in air as 
described previously .8
Animals
CD2Fj mice weighing 18-22 g were used as hosts 
for the L1210 leukemia and C57B1/6 mice were used 
for the B l6 melanoma tumor. In each experiment, 
phosphate-buffered saline (PBS)-treated tumor- 
bearing animals served as controls. All mice were 
obtained from Charles River Breeding Laboratories 
(Sulzfeld, Germany).
EDSM was synthesized at the department of Organic 
Chemistry, University of Nijmegen, The Nether­
lands, 13 and was acquired in a lyophilized form. 
The drug was dissolved in PBS and kept in dark 
flasks at 4°C. Seven drugs with different intracellular 
targets were selected for our combination studies: 
two S-phase specific antimetabolites, i.e. cytosar 
(Ara-C) and 5-fluorouracil (5-FU), one mitose-phase 
specific agent, i.e. vincristine (VCR), two topo- 
isomerase II inhibitors, i.e. etoposide (VP-16) and 
doxorubicin (DX), and two DNÀ crosslinking com­
pounds, i.e. cisplatin and carmustine (BCNU). Cis- 
platin and 5-FU were kindly provided by 
Pharmachemie BV (Haarlem, The Netherlands), 
BCNU and VP-16 were obtained from Bristol-Myers 
(Syracuse, NY), Ara-C from Upjohn (Kalamazoo, 
MI), VCR from Eli Lilly (Indianapolis, IN) and DX 
from Farmitalia (Milan, Italy). All drug solutions 
were prepared freshly before each use. The agents 
were dissolved in the prescribed solvent. Subse­
quently, solutions with the required drug concen­
tration were prepared from these stocks by dilution 
with isotonic NaCl just before administration.
Antitumor activity Statistical analysis
Mice were inoculated i.p. with 105 LI210 cells or 106 
B l6 melanoma cells suspended in 0.2 ml PBS, pH 
7.4. Acceptable control median survival times 
(MSTs) were 8- 1 1 days for the L1210 i,p, tumor 
model and 14-22 days for the B l6 i.p. tumor mod­
el,12 Tumor-bearing mice were randomized in the 
treatment and control group in each experiment. 
Each group consisted of six animals. Drugs were
Our experimental data have been analyzed by 
Cox’s proportional hazards regression model (PH 
m odel).M Each presented data point was calculated 
on the basis of repeated experiments. As usual, 
dummy variables were used in this PH model to 
indicate the given doses of EDSM and drugs. Pro­
duct terms of these dummy variables were included 
in the model to account for interaction effects of 
administered at various doses i.p. into mice using both drugs on survival. A tumor-specific hazard has
0.01 ml/g body weight. Different treatment sehe- been obtained by censuring death within 6 days for 
dules were used, starting on day 1, which was LI210 and within 14 days for B16 as due to drug
24 h after tumor implantation. Animal survival was 
recorded daily during 60 days and the MST of each
toxicity. This occurred only in some B l6 experi­
ments. For each treatment schedule the MSTs were 
group was calculated, Final antitumor results were calculated within this (complete) PH model. The 
computed as MST in days after tumor implantation. percentages of long-term survivors (LTSs) were also 
AT/C value of > 135% is generally taken as a po- calculated using the PH survival function and were
in very good agreement with the observed number 
of LTSs after 60 days. The risk ratios of individual as 
well as of combined drug treatments, compared 
with the non-treatecl animals, are directly given by 
PH analysis. All ƒ> values were calculated according 
to Wald’s x 2 P < 0.05 was considered to be
sitive indication for antitumor activity according to 
the NCI criteria.12 T/C is the MST of the test group 
divided by that of the control group. L1210 and B l6 
experiments were terminated after day 60. Mice 
alive at the end of an experiment were autopsied 
and judged to be cured if no signs of tumor were 
visible. significant.
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Results
Combined chemotherapy in B16 melanoma
The tumor-take of i.p. inoculated B16 melanoma 
was 100% and resulted in a MST of 18 ± 0.13 days 
for 66 placebo-treated control animals. B l6 mela­
noma is relatively resistant to single-drug treatment, 
except for DX, To determine whether EDSM could 
improve the antitumor activity of these drugs 
against B l6 melanoma in mice, we varied drug 
doses as well as the treatment schedules. The effect
any of the drugs studied, a pronounced effect was 
seen when EDSM was combined with DX, produ­
cing loss of the single-dose Cl mg/kg/injection) DX 
activity from 60 to 22 days, and reducing the number 
of LTSs from 4 to 0 (out of six animals). This antag­
onistic effect of EDSM was less obvious in combi­
nation with a DX dose of
Antitumor activity of EDSM in combination
Combined chemotherapy in L1210 leukemia
The treatment schedules of EDSM in combination
of EDSM was studied using doses of 2.5 or 5 mg with cytostatic agents were varied in several expert-
EDSM/kg, given on day 1, 4 and 7 (Dl,4,7) or on day ments performed with i.p. implanted L1210. The
1 , 5 and 9 (D l,5,9). The results of these experiments MST of 66 placebo-treated control animals was
are summarized in Table 1. Drug doses were in- 10 ± 0.35 days and the tumor-take was '100%.
creased until toxicity was observed. The classical EDSM at 5 mg/kg/injection showed a moderate
antitumor agents gave acceptable antitumor effects antitumor response by increasing the MST to 12
(>135% T/C, i.e. MST >  24 days, NCI protocol), days using the D l,5,9 treatment schedule whereas
except for Ara-C. The combination studies with no response was observed at 2,5 mg/kg/injection,
EDSM showed that in comparison with single-drug The results of combined drug treatment in L1210 are
treatment, none of the combinations gave improved 
results. Whereas our results showed that in this B l6
summarized in Table 2. Although we have described 
earlier14 that the modulatory capacity of EDSM in
tumor model EDSM is not capable of potentiating combination with cisplatin was independent of drug
Table 1. Dose- and schedule-dependent antitumor activity of several cytostatic agents in combination with EDSM against 
B16 melanoma (i.p.)
Drugs Treatment0 Doseb Single
MST (days) 
2.5 + EDSMb,c 5
Control 18 20 18
VCR D1,4,7 0.5 24 — 5 TOX
1.0 25 6 TOX
D1,5,9 0.25 20 22 6 TOX
0.50 20 22
0.75 22
VP-16 D1,4,7 10 32 6 TOX
D1,5,9 2.5 29 29 6 TOX
5.0 29 28 5 TOX
5-FU D1,4,7 50 23 — 7 TOX
100 TOX tom* 8 TOX
D1,5,9 50 19 19
01,8,15 100 22 19 —
ARA-C D1,4,7 50 19 19
100 19 — 18
Cisplatin D1,5,9 3 23 — 22
5 26 MM 13
TOX
DX D1,5,9 0.5 32 11B0 m m 22 0/6
1 60 4/6 mm 22 0/6
2 60 4/6 — 54 2/6
0 In the treatment schedules D1,4,7 and D1,5,9 these drugs were given I.p. on day 
implantation. 
b mg/kg/injection.
c EDSM was given I.p. 3 h after injection of the first drug.
d The MST of I.p.-implanted B16 melanoma was 18 ± 0.13 days for control animals.
1, 4 and 7 or on day 1, 5 and 9 after tumor
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Table 2. Antitumor activity of several cytostatic agents in L1210 leukemia (¡.p.), in combination with EDSM post-treatment 
after 3, 6 or 24 h (treatment schedule was D1>5,9; the number of animals treated is given in parentheses)
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Drugs Dose
(mg/kg/
injection)
Single drug 
MST3
+EDSM 2.5 mg/kg/injection p value
+3 h +6 h +24 h
Control 0 10 (66)
EDSM 2.5 10 (12)
VCR 0.5 32 (18) 24 (12) > 6 0  (12) > 6 0  (12) 0.04
1.0 46 (6) 18 (6) 0.23
5-FU 50 > 6 0  (18) 26 (12) > 6 0  (12) 30 (12) 0.16
Ara-C 100 1 4 (6 ) 14 (6) — _ 0.88
500 32 (18) 24 (12) 24 (12) > 5 5  (12) 0.008
BCNU 10 > 6 0  (12) > 6 0  (6) > 6 0  (6) > 4 4  (6) 0.63
DX 3 > 6 0  (24) > 6 0  (18) > 6 0  (6) > 6 0  (6) 0.20
a The MST of 66 placebo-treated control animals was 10 ± 0.35 days.
sequence administration as well as of time interval (p  « 0*008). Potentiation of the antitumor activity 
between drug administration, we now see the im- could not be measured due to maximal activity of 
portance of timing. In this L1210 model, EDSM mod- BCNU as a single drug. On the other hand, our
results show that EDSM has no antagonistic effect 
on the BCNU activity.
As in both tumor models DX is a very strong anti-
ified the antitumor activity of Ara-C, 5-FU and VCR, 
and the time interval between drug administration is 
crucial for potentiation of antitumor activity. Even 
an antagonistic effect was seen when EDSM was tumor agent on its own, we investigated the mod- 
given 3 or 24 h after 5-FU administration, although ulatory effect of EDSM in more detail using lower 
this antagonistic effect was not observed when DX doses. Table 3 shows the results of this study. 
EDSM was given 6 h after 5-FU. The MST of single EDSM (5 mg/kg) given before or after certain DX 
5-FU treatment was >60 days; therefore potential doses did not significantly improve the activity of
enhancement by EDSM could not be studied at this the latter drug. The overall p  value for EDSM pre-
5-FU dose. The antitumor activity of VCR, on the treatment was 0.97 and for EDSM post-treatment 
other hand, could be potentiated when EDSM was was 0.20. Finally, a reduction in DX antitumor ac-
given at least 6 h after VCR (Figure 1), thereby in­
creasing the MST from 32 to >60 days and the per­
centage survivors from 33 to 83% (p  -  0.04).
Potentiation of Ara-C’s antitumor activity was only 
noticed when the EDSM administration was post- Discussion 
poned until 24 h after the administration of Ara-C
tivity, as seen in the B16 model, was not noticed in 
the LI210 model.
(Figure 2), increasing the MST from 32 to >55 days 
and the percentage survivors from 1 1  to 50%
The results of the present study show that the mod­
ulating capacity of EDSM on antineoplastic agents is
Table 3. Effect of EDSM (5 mg/kg) on the antitumor activity of DX in L1210 (i.p.)
Dose D X 0 EDSM « 0 EDSM  = 5, - 3  hb EDSM = 5, +3 h
0
0.5
10° (66)d 
20 (12)
12 (48) 
21 (12) 14 (6)
1 19 (12) 19 (12) 17 (6)
2 19 (12) 19 (12) 44 (6)
3 > 6 0  (24) > 6 0  (18) > 6 0  (18)
4 23 (12) 24 (6) 
0.97'
18 (6) 
0.20'p value 0.00018
0 EDSM was given i.p. 3 h before or 3 h after DX injection.
b Treatment schedule was i.p. on day 1, 5 and 9 after tumor implantation (D1,5,9). 
c MST In days.
d Total number of animals used for analysis. 
e Overall p value for DX compared with the control level.
1 Overall p value of the combination compared with single DX treatment.
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Figure 1. Survival of mice inoculated I.p. with 105 L1210  
cells. Mice were treated i.p. with Ara-C (500 mg/kg/injec- 
tion) as a single drug ( □ )  and in combination with EDSM  
(2.5 mg/kg/injectlon), given 3 ( • ) ,  6 ( ♦ )  or 24 h ( ■ )  after 
Ara-C administration. Drug treatment started 24 h after tu­
mor implantation, once daily every 4 days for three doses. 
(O) Untreated control group.
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Figure 2, Survival of mice inoculated i.p. with 105 L1210 
cells. Mice were treated i.p. with VCR (0.5 mg/kg/injection) 
as a single drug ( □ )  and in combination with EDSM  
(2.5 mg/kg/injection), given 3 ( • ) ,  6 ( ♦ )  or 24 h (■ )  after 
VCR administration. Drug treatment started 24 h after tu­
mor implantation, once daily every 4 days for three doses, 
(O ) Untreated control group.
schedule dependent. The treatment schedule used or DX. No significant effects were found in combi-
in our experiments was based upon the results of 
the combination study of EDSM with cisplatin; ^
nation with BCNIJ or VP'16. In order to explain the 
occurrence of the chemomodulatory effects caused
these results were independent of time and order by EDSM we must consider the intercellular re- 
of drug administration, In combination with cis- sponse to treatment with the various drugs. Meta- 
platin EDSM could be given from 24 h before up holism of 5-FU produces two critical intermediates:
to 24 h after cisplatin injections, without loss of syn­
ergy.7 However, recent results from our laboratory 
revealed that when EDSM was combined in vitro 
with drugs other than cisplatin the outcome was
I /
dose and schedule dependent, } and synergism was 
most pronounced when EDSM was given as the 
second drug in the combination.
fluorouridine-S'-triphosphate (FUTP), which is in­
corporated into RNA and interferes with its function, 
and lluorodeoxyuridylate (FdUMP), which prevents 
normal DNA replication,17 5-FU is phase-specific for 
the S-phase of the cell cycle, which may explain
i  uwhy the effects of 5-FU are schedule dependent. 
The cytotoxic activity of Ara-C is due to its tripho-
In this report we discuss the efficacy of these drug sphorylated metabolite Ara-CTP, which blocks DNA
combinations in vivo in two murine tumor models. 
In contrast to what we have seen with cisplatin, the 
time interval between the administration of the two 
drugs is very important and determines w hether the 
antitumor activity of the classical cytostatic agents is 
potentiated or inhibited, These effects were most 
obvious in the combinations with 5-FU, Ara-C, VCR
synthesis through competitive inhibition of DNA
polymerase. Ara-C nucleotides may ais 
incorporated into DNA, 19 Intracellular deamination 
by the enzyme cytidine deaminase converts Ara-C 
to an inactive metabolite, uracil arabinoside (Ara- 
IJ). Hence Ara-C is also S phase-specific and again
J  A
its efficacy was shown to be schedule-dependent.
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Vincristine produces metaphase arrest by binding to 
tubulin, which results in a marked increase in the 
population of cells in mitosis, which is maximal 6-
^  a ^
12 h after drug administration." Inhibitors of pro­
tein synthesis are known to cause a reversible cell- 
cycle arrest in Gj., and as long as tumor cells 
remain in Gj, no antitumor activity of S plvase-spe- tivity of BCNU. This effect is dependent on the turn- 
cilic agents like 5-FU and Ara-C can be expected, over time of this alkyltransferase. In the L1210 tumor 
This might be the rational for the reduction in anti- model BCNU by itself gave complete antitumor re­
tumor activity that we observed when EDSM was sponses at a dose of 10 mg/kg. Thus, improvement 
given too soon (3 h) after the first drug, blocking the by EDSM cannot be expected under these condi- 
cell transfer from G* to S phase. In addition, protein tions. On the other hand, our results did not show
HP Hofs e t  al.
kyltransferase. The use of a direct alkyltransferase 
inhibitor, such as 06-methylguanine, inactivates the 
alkyltransferase and sensitizes cells to BCNU,''5 
One of the effects of EDSM might be based on an 
inhibition of tie novo synthesis of this repair enzyme 
and thereby indirectly increasing the antitumor ac-
synthesis inhibition may also decrease the cellular 
deaminase activity, which leaves more Ara-C nu­
cleotides to be incorporated into DNA, increasing 
the cytotoxicity of Ara-C, assuming that the phos­
phorylation of Ara-C by nucleoside mono- and di­
phosphate kinase is not inhibited. On the other 
hand, if EDSM was given before Ara-C treatment 
the DNA-replicative synthesis would have been re- 
versibly turned down by EDSM as well as the phos­
phate kinase activity, and temporarily the
any antagonistic interaction between EDSM and 
BCNIJ, as was clearly observed in the combination 
with 5 -FU,
The two tumor models used in this report are 
hardly comparable, L1210 leukemia is a rapidly 
growing tumor with a high percentage of cells 
synthesizing DNA. Because all cells are actively 
progressing through the cell cycle, its life cycle is 
consistent and predictable.3 The relationship 
between cell number and survival in L1210 leuke-
intraceliular Ara-C molecules cannot be incorpora- mia is linear. The time to death of animals bearing
ted into DNA, which thus means loss of Ara-C anti­
tumor activity. These biochemical implications 
indicate the importance of timing when EDSM is 
given in combination with 5-FU, Ara-C or VCR. In
LI 210 leukemia is the interval required to achieve a 
population size of about 109 cells. With a growth 
fraction of 100%, 109 cells will accumulate by 10 
days after the injection of 105 cells. The i.p.
this context the synergism of EDSM and cisplatin inoculated B16 melanoma cells will grow as a solid
tumor, have a longer cell cycle and therefore grow 
less rapidly than L1210 cells. Injection of 10rt cells 
glutathione-S-transferases and/or inhibition of the requires 18 days to reach lethality. This tumor model
could, for instance, result from glutathione deple­
tion by EDSM, inhibition of de novo synthesis of
repair of cisplatin-induced DNA damage, The ap­
parent induction by EDSM of the cytotoxic effects of 
DX and BCNU is less obvious. The mechanism of 
cytotoxicity of doxorubicin is very complex, in-15 yi
eluding inhibition of DNA synthesis, DNA inter­
calation,25“ 27 DNA single-strand breaks,28 the 
production of superoxide free radicals binding 
to the cell membrane and altering its function,30 
and interaction with topoisomerase II.29,31,32 EDSM 
might contribute to this cytotoxicity by inhibition of has no measurable antitumor activity against B16 
de novo  topo II synthesis and DNA repair proteins, tumors, probably because, contrary to the L1210 
but the extent of these effects can only be small to cell cycle time, the reversible inhibition of protein 
effect the miscellaneous DX targets and the strong synthesis does not last long enough to cause 
activity of DX as a single drug in L1210 as well as measurable problems for the viability of B16 tumor 
B16 melanoma. BCNU, on the other hand, under­
goes spontaneous chemical degradation to a carbo-
has a low percentage of cells synthesizing DNA and 
will he less sensitive to S phase-specific drugs like 
5-FU and Ara-C, Moreover, in the L1210 model 
drug treatment starts on day 1 and continues until 
the number of tumor cells in control animals 
has reached the maximum cell number, The B l6 
tumor model is more advanced ( 106 cells) at the 
start and the last drug treatment is given 9 days 
before MST of the control animals. EDSM by itself
\ I <'
Summarizing, we can conclude that modulation 
nium ion that alkylates DNA and an isocyanate of antitumor activity by EDSM is tumor-type-depen-
intermediate that carbamoylates proteins, such as 
DNA repair enzymes.33,34 DNA alkylation by BCNU
dent and is limited to cell-cycle phase-specific drugs 
like Ara-C and VCR, with the exception that it also
subsequently results in DNA crosslinking, which is potentiates the activity of cisplatin. Moreover, this
critical for cancer cell lethality. The cytotoxic DNA 
damage induced by BCNU is normally repaired by 
the DNA repair enzyme O ’-alkylguanine-DNA al-
report shows that the antitumor activity of drug 
combinations depends on the timing of the drug 
administration.
282 Anti-Cancer Drugs • Voi 6 • 7995
A nt Humor activity o f HDSM in combination
Acknowledgments
We are very grateful to Dr Koopmans and his co­
workers of the Central Animal Laboratory for excel­
lent animal care and assistance during these experi­
ments.
References
1. Bitonti AJ, Kelly SK, Flynn GA, at al, Inhib ition  o f  Try­
pan osom a bnicei  peptidyl transferase  activity by s p a r ­
som ycin analogues and  effects o n  trypanoso ine  p ro te in  
synthesis and  proliferation. B tacbem  Pharm acol  1985; 
34: 3055-60.
2. Contreras A, Carrasco L Selective inhibition o f  p ro te in  
synthesis in virus-infected m am m alian  cells, J Virol 1979; 
29: 114—22.
3. G oldberg  III, Mitsugi K. Inhib ition  by  sparsom ycin  a n d  
o ther antibiotics of the p iirom yein -indueed  re lease  o f 
po lypep tide  from ribosom es. Biochemistry  1967; 6 :
383-91.
4. Tada K, Trakatellis AC. M echanism  of action o f  sp a rso -  
mycin on  protein  synthesis, A n tim icroh  Ag C hem otber  
1970; 3: 227-30.
5. Zylicz Z, W agener DJTh, R ennes H  van, el a l  in  vivo  
poten tia tion  of cft-d iam m ined ich lorop la tinum  (II) anti- 
tum our activity by p re trea tm en t w ith  sparsom ycin . C a n ­
cer Lett 1986 ; 3 2 : 53-9.
6 . Zylicz Z, Hofs HP, W agener DJTh, Po ten tia tion  o f  cis­
platin an titum our activity on L I210 leukaem ia  s x .  by  
Sparsom ycin and  three of its an a lo g u es . C ancer Lett
1989; 46: 153-7.
7. Hofs HP, W agener DJTh, Valk-Bakker V tie, et a l  P o ­
tentiation of cisplatin an titum our activity by e thy ldeshy - 
droxy-sparsom ycin  in LI210 leu kaem ia . A nticancer Res 
1992; 12: 167-70.
8 . Hofs HP, W agener DJTh, V alk-Bakker V cle, et til  C or­
relation of the in vitro cytotoxicity  o f  e thy ldeshydroxy- 
sparsom ycin  and cisplatin with the  in vivo  an ti tu m o u r  
activity in m urine L I210 leukaem ia  a n d  two resistan t 
LI 210 subclones. Cancer Chemother Pharm acol  1993; 
31: 289-94.
9. O zaw a S, Yasuda T, Inaba M. C om parison  o f  cellu lar 
basis of drug sensitivity of hum an  co lon , pancreatic , a n d  
renal carcinom a cell lines with tha t o f  leukaem ia cell 
lines. Cancer Che mot her P harm acol  1988; 22: 41-6 .
10. D aoud SS, Forde Nil. Synergistic cytotoxic ac tions o f  
cisplatin and liposomal valinom yefn o n  hum an ovarian  
eareinom a cells. Cancer ChemotbvrlHutrmacol  1991; 28: 
370-6.
11. Jayaram  HN, M urayama K, Pillwein K, at a l  S chedu le-  
d e p e n d e n t  synergistic action of tiazofurin  ami d ipy rida-  
m ole o n h e p a to m a 3924 A cells. Ca n cer Ch e mot her Pha r- 
macol  1992; 31: 93-6.
12. G eran RI, G reenberg  NH, M acdonald  MM, et a  I Pro to­
cols fo r  screening chemical agents a n d  natural p ro d u c ts  
against a n im a l tumours a n d  o ther biological systems, 
3rd edn. Cancer Chemotber Rep 1972; 3: no. 2.
13. Broek LAGM van den, Lazaro H, Zylicz Z, el a t  L ipophilic  
analogues of sparsom ycin  as s tro n g  inhibitors o f  p ro te in  
synthesis and tum our growth: a s truc tu re -ae tiv ity  rei a-
tionsh ip  s tudy . J Med Cbem 1989; 32: 2002-15.
14. Kalbfleisch JD , Prentice RI,. The statistical analysis o f  
fa i lu re - t im e  data.  New York: Wiley 1980,
15. H ofs HP, W agener DJTh, Valk-Bakker V de, et a l  Pre- 
clinical a n ti tu m o u r  activity of ethyldeshydroxy-sparso- 
mycin in com bina tion  with cisplatin. Invest New D m gs  
1994; in p ress .
16. Hofs HP, W agener DJTh, Vaik-Bakker V de et al, C on­
cen tra tion  a n d  seq u en ce  d ependen t synergism o f ethyl- 
d e sh y d ro x y -sp a rso m y d n  in com bination with anti­
tu m o u r agen ts . Anti-Cancer Drugs 1994; 5: 35-42,
17. Arda la n 15, G lazer  R. An update on the biochem istry o f  5- 
fluorouraciL  C ancer  'Treat Rev 1981; 8 : 157-67.
18. Fraile KJ, B aker LH, BurokerTU, et al, Pharm acokinetics 
o f  5-fluom uracil administered orally, by rapid intrave­
nous  a n d  by  s low  infusion. Cancer Res 1980; 40: 2223-8.
19. Ross DD, T h o m p so n  BW, Joneckis CC, et a l  Metabolism 
o f  Ara-C by b last cells from patients with ANLL. Blood  
1986; 6 8 : 78 -82 .
20. Carlson KW, Sikic BI, Continuous infusion or bolus in­
jection in c a n c e r  chem otherapy. Ann Intern Med  1983;
99: 823-33.
21. Frei III IÎ, W h an g  J, Scoggins RB, el a l  The suuhm o- 
kinetic effect o f  vincristine. Cancer Res 1964; 24: 191H— 
25.
22. I-I rom as RÀ, Y ung WKA, Anguidine potentiates cispla- 
tinum  in h u m a n  brain tumour cells. JNeuro-Oncal  1986; 
3: 343-8.
23. T eodori L, B arlogie  B, Drewinko B, el a l  Reduction of 1 - 
/J-D-arabinofuranosylcytosinc and adriam ycine cytoxicity 
fo llow ing cell cycle arrest by anguidine. Cancer Res 
1981; 41: 1263-70.
24. C rooke ST, D uvernay  VII, Galvan L, et a l  S tructu re- 
activity re la tion sh ip s  of anthracyclines relative to effects 
o n  m acro  m o lecu la r  synthesis. Mol Pharmacol 1978; 14: 
290-8.
25. Pigram  WJ, Fuller W, Hamilton LD. Stereochemistry 
o f  in terca la tion : interaction of daunom ycin  with DNA. 
N ature  1972; 235: 17-9.
26. Q uig ley  GJ, W ang AHJ, Ughetto G, et al. M olecular 
s truc tu re  o f  an  anticancer drug-DNA complex. Proc Natl 
A c a d  Sci USA 1980; 77: 7204-8.
27. Z un ino  F, Di M arco A, Zaceara A, et al, The interaction o f 
d a u n o ru b ic in  a n d  doxorubicin with DNA and  chromatin. 
Biochim B iopbys Acta  1980; 607: 206-14.
28. Zw elling LA, Michaels S, Kriekson LC, et al. Protein- 
assoc ia ted  deoxyribonucleic  acid strand breaks in 
LI 210 cells  trea ted  with the deoxyribonucleic acid inter­
calating ag en ts  4 ' - (  9-a crid i ny la m 1 no ) m e thaï h i s  u  I fon-m -  
an is id ide  a n d  adriamycin. Biochemistry 1981; 20:
6553-63 .
29. Mu indi JRF, Sinha HK, Gianni L, el a l  Hydroxyl radical 
p ro d u c tio n  a n d  DNA damage induced by anthracyclines. 
PUBS Letl 1984; 172: 226-30.
30. Tritton TR, M urphree  SA, Sartorelli AC. Adriamycin: a 
p ro p o sa l o n  the specificity of drug action. Biochem Bio­
p b y s  Res C om m un  1978; 84: 802-8.
31. Deffie AM, Batra JA, Goldenberg GJ, Direct correlation 
b e tw e e n  DNA topoisom erase II activity and cytotoxicity 
in adriam yciivsensitive  and -resistant P388 leukaem ia 
cell lines. C a n cer  Res 1989; 49: 58-62,
32. P om m ier Y, Schw artz  RK, Kohn KW, et al. Formation and  
rejo ining o f  deoxyribonucleic  acid d o u b len t rand  breaks 
in d u ced  in iso la ted  cell nuclei by anti neoplastic inter-
Anti-Cancer Drugs ■ Vo I 6 • 799') 283
cala ting agen ts . Biochemistry  1984; 23: 3194-201.
33. K ann HE, K ohn  KW, Lyles TM. Inhib ition  o f  DNA repa ir  
by the 1 ,3 -bis ( 2-ch lo roe thyD -I-n itro sou reas  b reakdow n 
p roduc t, 2 -ch lo roethy l isocyanate . Cancer Res 1974; 34: 
398-402,
34. W h ee le r  GP, C hum ley  S. Alkylating activity of l,3-bis(2~ 
c h lo ro e th y lM -n itro so u re a  and  se lec ted  com pounds. 
J  Med Cbem  1967; 1 0 : 259-61,
35. G erson  SL, Z b o ro w sk a  E, N orton K, et al. Synergistic
HP Hofs et al,
36.
efficacy of 0 C)-benzylguanine and  l , 3-b is(2-chloroethyl)- 
1-nitrosourea (BCNU) in a hum an  co lon  cancer xeno ­
graft com pletely resistant to BCNIJ alone, Biochem Phar­
m aco l  1993; 45: 483-91.
Y ankee RA, DeVita VT, Perry S. The cell cycle of leu­
kaem ia  LI 210 cells in vivo, Cancer Res 1968; 27: 2381-5.
(Received 20 October 1994; accepted 15 December
1994)
284 Anti-Cancer Drugs • Voi 6 • 1995
